Skip to Main Content
Phase I

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

  • Study HIC#:2000022408
  • Last Updated:10/13/2021

This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.

  • Start Date06/21/2020
  • End Date06/01/2023

Trial Purpose and Description

ASTX029 is a synthetic small molecule inhibitor of extracellular signal-regulated kinases (ERKs) 1/2. ASTX029 has not been previously evaluated in human subjects. The Phase 1 portion of this study will assess safety and determine the maximum tolerated dose, the recommended Phase 2 dose (RP2D), and the recommended dosing regimen of ASTX029 administered orally. The Phase 2 portion will assess preliminary clinical activity in tumors characterized by gene aberrations in the mitogen-activated protein kinase (MAPK) signal pathway that may confer sensitivity to ASTX029.

Eligibility Criteria

Inclusion Criteria:

Subjects must fulfill all of the following inclusion criteria.

  1. Able to understand and comply with study procedures, understand the risks involved in the study, and provide written informed consent before any study-specific procedure is performed.
  2. Men or women 18 years of age or older.
  3. Subjects with histologically or cytologically confirmed advanced solid tumors that are metastatic or unresectable, who are refractory or have relapsed after treatment with available therapies or for whom standard life-prolonging measures or approved therapies are not available. In Phase 1 Part B (except in the potential food-effect cohort) and in the Phase 2 portion of the protocol, subjects must also have documented gene alterations in the MAPK pathway as detailed in the protocol.
  4. In Phase 1 Part B (except in the potential food-effect cohort) of the protocol, subjects must have disease lesions that are amenable to biopsy.
  5. In the Phase 2 portion of the protocol, subjects must have measurable disease according to RECIST v1.1.
  6. Eastern Cooperative Oncology Group performance status 0 to 2.
  7. Acceptable organ function as evidenced by the following laboratory data:
    1. Aspartate aminotransferase and alanine aminotransferase ≤2×upper limit of normal (ULN) or ≤3 ULN in the presence of liver metastases.
    2. Total serum bilirubin ≤1.5×ULN.
    3. Absolute neutrophil count ≥1500 cells/mm3.
    4. Platelet count ≥100,000 cells/mm3.
    5. Calculated creatinine clearance (by the standard Cockcroft Gault formula) of ≥50 mL/min or glomerular filtration rate of ≥50 mL/min.
  8. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group as detailed in the protocol) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures (as described in the protocol) during the study and for at least 3 months after completing treatment and must agree not to become pregnant or father a child while receiving study treatment and for at least 3 months after completing treatment.

Exclusion Criteria:

  1. Hypersensitivity to ASTX029 or excipients of the drug product.
  2. Poor medical risk in the investigator's opinion because of systemic diseases in addition to the cancer under study, for example, uncontrolled infections.
  3. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise subject safety or the integrity of study outcomes or interfere with the absorption or metabolism of ASTX029.
  4. Prior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX029), as follows:
    1. Cytotoxic chemotherapy or radiotherapy within 3 weeks prior and any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to ≤Grade 1.
    2. Monoclonal antibodies within 4 weeks prior and any encountered treatment-related toxicities not resolved to ≤Grade 1.
    3. Molecularly targeted drug or investigational drugs, without the potential for delayed toxicity, within 4 weeks of the first dose of study treatment or 5 half-lives (minimum 14 days), whichever is shorter.
  5. Prior treatment with ERK inhibitors.
  6. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:
    1. Abnormal left ventricular ejection fraction (<50%) on echocardiogram or multiple-gated acquisition scan.
    2. Congestive cardiac failure of ≥Grade 3 severity according to New York Heart Association functional classification defined as patients with marked limitation of activity and who are comfortable only at rest.
    3. Unstable cardiac disease including unstable angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).
    4. History or evidence of long QT interval corrected for heart rate (QTc), ventricular arrhythmias including ventricular bigeminy, complete left bundle branch block, clinically significant bradyarrhythmias such as sick sinus syndrome, second- and third-degree atrioventricular block, presence of cardiac pacemaker or defibrillator, or other significant arrhythmias.
    5. Screening 12-lead electrocardiogram with measurable QTc interval of ≥470 msec. (Fridericia's formula should be used to calculate the QTc interval throughout the study.)
  7. Known history of human immunodeficiency virus infection or seropositive results consistent with active hepatitis B virus or active hepatitis C virus infection.
  8. Known brain metastases, unless previously treated and stable for at least 3 months with or without steroids.
  9. Known significant mental illness or other conditions, such as active alcohol or other substance abuse that, in the opinion of the investigator, predispose the subject to high risk of noncompliance with the protocol treatment or assessments.
  10. History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) including:
    1. Presence of predisposing factors to RVO or CSR (eg, uncontrolled glaucoma or ocular hypertension, uncontrolled diabetes mellitus) or
    2. Visible retinal pathology as assessed by ophthalmic examination at screening that is considered a risk factor for RVO or CSR such as:
      • Evidence of optic disc cupping or
      • Evidence of new visual field defects on automated perimetry or
      • Intraocular pressure >21 mmHg as measured by tonography.

For more information about this study, contact:

Or contact the Help us Discover team on: